Alejo Rodríguez‐Vida
About
Alejo Rodríguez‐Vida is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Surgery.
According to data from OpenAlex, Alejo Rodríguez‐Vida has authored 95 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 57 papers in Pulmonary and Respiratory Medicine, 47 papers in Oncology and 41 papers in Surgery. Recurrent topics in Alejo Rodríguez‐Vida's work include Bladder and Urothelial Cancer Treatments (41 papers), Prostate Cancer Treatment and Research (34 papers) and Cancer Immunotherapy and Biomarkers (31 papers). Alejo Rodríguez‐Vida is often cited by papers focused on Bladder and Urothelial Cancer Treatments (41 papers), Prostate Cancer Treatment and Research (34 papers) and Cancer Immunotherapy and Biomarkers (31 papers). Alejo Rodríguez‐Vida collaborates with scholars based in Spain, United States and United Kingdom. Alejo Rodríguez‐Vida's co-authors include Joaquim Bellmunt, Thomas E. Hutson, Michiel Strijbos, Simon Chowdhury, Johann S. de Bono, Diletta Bianchini, David Lorente, Aurelius Omlin, Gerhardt Attard and Roberta Ferraldeschi and has published in prestigious journals such as Journal of Clinical Oncology, Scientific Reports and Clinical Cancer Research.
In The Last Decade
Alejo Rodríguez‐Vida
85 papers receiving 1.1k citations
Peers
Alejo Rodríguez‐Vida
Arash Rezazadeh Kalebasty United States
Dingwei Ye China
Xiao X. Wei United States
Satoshi Fukasawa Japan
Michael Kolinsky Canada
Daygen L. Finch Canada
Hamid Emamekhoo United States
Rosa Nadal United States
Anders Ullén Sweden
Kevin Beja Canada
Citations per year, relative to Alejo Rodríguez‐Vida Alejo Rodríguez‐Vida (= 1×)
peers
Arash Rezazadeh Kalebasty
Countries citing papers authored by Alejo Rodríguez‐Vida
Since
Specialization
Citations
This map shows the geographic impact of Alejo Rodríguez‐Vida's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alejo Rodríguez‐Vida with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alejo Rodríguez‐Vida more than expected).
Fields of papers citing papers by Alejo Rodríguez‐Vida
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Alejo Rodríguez‐Vida. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alejo Rodríguez‐Vida. The network helps show where Alejo Rodríguez‐Vida may publish in the future.
Co-authorship network of co-authors of Alejo Rodríguez‐Vida
This figure shows the co-authorship network connecting the top 25 collaborators of Alejo Rodríguez‐Vida. A scholar is included among the top collaborators of Alejo Rodríguez‐Vida based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Alejo Rodríguez‐Vida. Alejo Rodríguez‐Vida is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Bellmunt, Joaquim, Júlia Perera‐Bel, Gardenia Vargas‐Parra, et al.. (2025). Prognostic Value of PARP1 and PARP2 Copy Number Alterations in Prostate Cancer. Laboratory Investigation. 105(6). 104171–104171.
2.
Carles, Joan, Bertrand Tombal, Maha Hussain, et al.. (2025). Age-related efficacy and safety of darolutamide plus androgen-deprivation therapy (ADT) and docetaxel in patients with metastatic hormone-sensitive prostate cancer (mHSPC): A subgroup analysis of ARASENS.. Journal of Clinical Oncology. 43(5_suppl). 143–143.
3.
Vulsteke, Christof, Pongwut Danchaivijitr, Alejo Rodríguez‐Vida, et al.. (2025). LBA2 Perioperative (periop) enfortumab vedotin (EV) plus pembrolizumab (pembro) in participants (pts) with muscle-invasive bladder cancer (MIBC) who are cisplatin-ineligible: The phase III KEYNOTE-905 study. Annals of Oncology. 36. S1648–S1648.
4.
Powles, Thomas, Michiel S. van der Heijden, Shilpa Gupta, et al.. (2024). 1966MO EV-302: Exploratory analysis of nectin-4 expression and response to 1L enfortumab vedotin (EV) + pembrolizumab (P) in previously untreated locally advanced or metastatic urothelial cancer (la/mUC). Annals of Oncology. 35. S1137–S1138.
5.
Gillessen, Silke, Ananya Choudhury, Ray McDermott, et al.. (2024). LBA1 A randomized multicenter open label phase III trial comparing enzalutamide vs a combination of Radium-223 (Ra223) and enzalutamide in asymptomatic or mildly symptomatic patients with bone metastatic castration-resistant prostate cancer (mCRPC): First results of EORTC-GUCG 1333/PEACE-3. Annals of Oncology. 35. S1254–S1254.
6.
Voss, Martin H., Benjamin Garmezy, J.P. Maroto Rey, et al.. (2023). 1883MO MEDI5752 (volrustomig), a novel PD-1/CTLA-4 bispecific antibody, in the first-line (1L) treatment of 65 patients (pts) with advanced clear cell renal cell carcinoma (aRCC). Annals of Oncology. 34. S1012–S1012.
7.
Garralda, Elena, Do Youn Oh, Antoîne Italiano, et al.. (2023). Pharmacokinetics (PK) of Tiragolumab in First‐in‐Human Study in Patients with Mixed Solid Tumors (GO30103). The Journal of Clinical Pharmacology. 64(5). 544–554.
8.
Juanpere, Núria, Marta Lorenzo, David López, et al.. (2023). Immunohistochemical markers as predictors of prognosis in multifocal prostate cancer. Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin. 485(2). 281–290.
9.
Rodríguez‐Vida, Alejo, Syed A. Hussain, Carlos Álvarez-Fernández, et al.. (2023). 2363MO A phase II study investigating the safety and efficacy of neoadjuvant atezolizumab in non-urothelial, muscle invasive bladder cancer (ABACUS-2). Annals of Oncology. 34. S1201–S1202.
10.
Auclin, Édouard, Anna Patrikidou, Laura Mezquita, et al.. (2023). Prognostic Value of the Lung Immune Prognosis Index Score for Patients Treated with Immune Checkpoint Inhibitors for Advanced or Metastatic Urinary Tract Carcinoma. Cancers. 15(4). 1066–1066.
11.
Rodriguez, J.M. Piulats, Juan Manuel Sepúlveda-Sánchez, Teresa Alonso Gordoa, et al.. (2023). 1783P PROSTRATEGY: A SOGUG randomized trial of androgen deprivation therapy (ADT) plus docetaxel (dct) +/- nivolumab (nivo) or ipilimumab-nivolumab (ipi-nivo) in high-volume metastatic hormone-sensitive prostate cancer (hvHSPCa) - Efficacy results from the pilot phase. Annals of Oncology. 34. S963–S964.
12.
Jiménez, Natàlia, Òscar Reig, Mercedes Marín‐Aguilera, et al.. (2022). Transcriptional Profile Associated with Clinical Outcomes in Metastatic Hormone-Sensitive Prostate Cancer Treated with Androgen Deprivation and Docetaxel. Cancers. 14(19). 4757–4757.
13.
Rodríguez‐Vida, Alejo, A. Rodríguez Alonso, Fernando López‐Campos, et al.. (2021). Impact of New Systemic Therapies in Overall Survival in Non-Metastatic Castration Resistant Prostate Cancer: Systematic Review and Meta-Analysis. Clinical Genitourinary Cancer. 20(2). 197.e1–197.e10.
14.
Epaillard, Nicolas, Yohann Loriot, Pernelle Lavaud, et al.. (2021). Treatments Outcomes in Histological Variants and Non-Urothelial Bladder Cancer: Results of a Multicenter Retrospective Study. Frontiers in Oncology. 11.
15.
Alva, Ajjai, Tibor Csőszi, Mustafa Özgüroğlu, et al.. (2020). LBA23 Pembrolizumab (P) combined with chemotherapy (C) vs C alone as first-line (1L) therapy for advanced urothelial carcinoma (UC): KEYNOTE-361. Annals of Oncology. 31. S1155–S1155.
16.
Szabados, Bernadett, Alejo Rodríguez‐Vida, Ignacio Durán, et al.. (2020). 199O A phase II study investigating neoadjuvant atezolizumab in cisplatin-ineligible patients with muscle-invasive bladder cancer: Final analysis. Annals of Oncology. 31. S1319–S1319.
17.
Jiménez, Natàlia, Òscar Reig, Giancarlo Castellano, et al.. (2020). 1971P Neuroendocrine (NE) expression profiling in non-castrate tumours is associated with poor therapy benefit and adverse clinical outcome in metastatic castration-resistant prostate cancer (mCRPC) patients. Annals of Oncology. 31. S1107–S1107.
18.
Rodríguez‐Vida, Alejo, Núria Juanpere, Oriol Arpí, et al.. (2019). Novel Oral mTORC1/2 Inhibitor TAK-228 Has Synergistic Antitumor Effects When Combined with Paclitaxel or PI3Kα Inhibitor TAK-117 in Preclinical Bladder Cancer Models. Molecular Cancer Research. 17(9). 1931–1944.
19.
Rodríguez‐Vida, Alejo, Matilde Saggese, Simon Hughes, et al.. (2015). Complexity of FGFR signalling in metastatic urothelial cancer. Journal of Hematology & Oncology. 8(1). 119–119.
20.
Rodríguez‐Vida, Alejo, et al.. (2013). The role of metastasectomy in renal cell carcinoma. Expert Review of Anticancer Therapy. 13(12). 1363–1371.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Arash Rezazadeh Kalebasty Breakdown of academic impact, for papers by Dingwei Ye Breakdown of academic impact, for papers by Xiao X. Wei Breakdown of academic impact, for papers by Satoshi Fukasawa Breakdown of academic impact, for papers by Michael Kolinsky Breakdown of academic impact, for papers by Daygen L. Finch Breakdown of academic impact, for papers by Hamid Emamekhoo Breakdown of academic impact, for papers by Rosa Nadal Breakdown of academic impact, for papers by Anders Ullén Breakdown of academic impact, for papers by Kevin Beja